314 related articles for article (PubMed ID: 1660140)
1. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin.
Ashkenazi A; Marsters SA; Capon DJ; Chamow SM; Figari IS; Pennica D; Goeddel DV; Palladino MA; Smith DH
Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10535-9. PubMed ID: 1660140
[TBL] [Abstract][Full Text] [Related]
2. Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: comparison with anti-TNF monoclonal antibody.
Jin H; Yang R; Marsters SA; Bunting SA; Wurm FM; Chamow SM; Ashkenazi A
J Infect Dis; 1994 Nov; 170(5):1323-6. PubMed ID: 7963738
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody.
Haak-Frendscho M; Marsters SA; Mordenti J; Brady S; Gillett NA; Chen SA; Ashkenazi A
J Immunol; 1994 Feb; 152(3):1347-53. PubMed ID: 8301136
[TBL] [Abstract][Full Text] [Related]
4. Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins.
Scallon BJ; Trinh H; Nedelman M; Brennan FM; Feldmann M; Ghrayeb J
Cytokine; 1995 Nov; 7(8):759-70. PubMed ID: 8664442
[TBL] [Abstract][Full Text] [Related]
5. Minimal tumor necrosis factor receptor binding protein: optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-IgG fusion protein.
Corcoran AE; Scallon BJ; Trinh H; Chernajovsky Y; Ghrayeb J; Feldmann M
Eur Cytokine Netw; 1998 Sep; 9(3):255-62. PubMed ID: 9831174
[TBL] [Abstract][Full Text] [Related]
6. Distinct roles of the two tumor necrosis factor (TNF) receptors in modulating TNF and lymphotoxin alpha effects.
Medvedev AE; Espevik T; Ranges G; Sundan A
J Biol Chem; 1996 Apr; 271(16):9778-84. PubMed ID: 8621658
[TBL] [Abstract][Full Text] [Related]
7. The pharmacology study of a new recombinant TNF receptor-hyFc fusion protein.
Lee JH; Cho JH; Yeo J; Lee SH; Yang SH; Sung YC; Kang JH; Park CS
Biologicals; 2013 Mar; 41(2):77-83. PubMed ID: 23190454
[TBL] [Abstract][Full Text] [Related]
8. A recombinant tumor necrosis factor-alpha p80 receptor:Fc fusion protein decreases circulating bioactive tumor necrosis factor-alpha but not lung injury or mortality during immunosuppression-related gram-negative bacteremia.
Lechner AJ; Johanns CA; Matuschak GM
J Crit Care; 1997 Mar; 12(1):28-38. PubMed ID: 9075062
[TBL] [Abstract][Full Text] [Related]
9. Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding.
Marsters SA; Frutkin AD; Simpson NJ; Fendly BM; Ashkenazi A
J Biol Chem; 1992 Mar; 267(9):5747-50. PubMed ID: 1313418
[TBL] [Abstract][Full Text] [Related]
10. Lymphotoxin-alpha-deficient and TNF receptor-I-deficient mice define developmental and functional characteristics of germinal centers.
Matsumoto M; Fu YX; Molina H; Chaplin DD
Immunol Rev; 1997 Apr; 156():137-44. PubMed ID: 9176705
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis.
Evans TJ; Moyes D; Carpenter A; Martin R; Loetscher H; Lesslauer W; Cohen J
J Exp Med; 1994 Dec; 180(6):2173-9. PubMed ID: 7964492
[TBL] [Abstract][Full Text] [Related]
12. The release of soluble p55 TNF receptor from U937 cells studied by a new p55 immunoassay.
Liabakk NB; Sundan A; Lien E; Laegreid A; Bombara MP; Ranges G; Espevik T
J Immunol Methods; 1993 Aug; 163(2):145-54. PubMed ID: 8394856
[TBL] [Abstract][Full Text] [Related]
13. A non-competitive P55 TNF receptor antibody enhances the specific activity of lymphotoxin-alpha.
Medvedev AE; Laegreid A; Sundan A; Espevik T
Scand J Immunol; 1996 Apr; 43(4):439-48. PubMed ID: 8668924
[TBL] [Abstract][Full Text] [Related]
14. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.
Mohler KM; Torrance DS; Smith CA; Goodwin RG; Stremler KE; Fung VP; Madani H; Widmer MB
J Immunol; 1993 Aug; 151(3):1548-61. PubMed ID: 8393046
[TBL] [Abstract][Full Text] [Related]
15. The opioid antagonist naltrexone blocks acute endotoxic shock by inhibiting tumor necrosis factor-alpha production.
Greeneltch KM; Haudenschild CC; Keegan AD; Shi Y
Brain Behav Immun; 2004 Sep; 18(5):476-84. PubMed ID: 15265541
[TBL] [Abstract][Full Text] [Related]
16. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.
Fisher CJ; Agosti JM; Opal SM; Lowry SF; Balk RA; Sadoff JC; Abraham E; Schein RM; Benjamin E
N Engl J Med; 1996 Jun; 334(26):1697-702. PubMed ID: 8637514
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock.
Shimamoto Y; Chen RL; Bollon A; Chang A; Khan A
Immunol Lett; 1988 Apr; 17(4):311-7. PubMed ID: 3372010
[TBL] [Abstract][Full Text] [Related]
18. Implication of TNF receptor-I-mediated extracellular signal-regulated kinases 1 and 2 (ERK1/2) activation in growth of AIDS-associated Kaposi's sarcoma cells: a possible role of a novel death domain protein MADD in TNF-alpha-induced ERK1/2 activation in Kaposi's sarcoma cells.
Murakami-Mori K; Mori S; Bonavida B; Nakamura S
J Immunol; 1999 Mar; 162(6):3672-9. PubMed ID: 10092829
[TBL] [Abstract][Full Text] [Related]
19. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection.
Pfeffer K; Matsuyama T; Kündig TM; Wakeham A; Kishihara K; Shahinian A; Wiegmann K; Ohashi PS; Krönke M; Mak TW
Cell; 1993 May; 73(3):457-67. PubMed ID: 8387893
[TBL] [Abstract][Full Text] [Related]
20. Development of a baculovirus expression system for soluble porcine tumor necrosis factor receptor type I and soluble porcine tumor necrosis factor receptor type I-IgG fusion protein.
Mwangi SM; Stabel TJ; Kehrli ME
Vet Immunol Immunopathol; 2002 Jul; 86(3-4):251-4. PubMed ID: 12007891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
